Arcturus Therapeutics (NASDAQ:ARCT) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Arcturus Therapeutics (NASDAQ:ARCT) from a strong sell rating to a sell rating in a research note published on Saturday morning.

Separately, Weiss Ratings raised shares of Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $24.25.

Arcturus Therapeutics Trading Down 2.1%

Arcturus Therapeutics stock opened at $6.05 on Friday. Arcturus Therapeutics has a 12-month low of $5.85 and a 12-month high of $24.17. The firm has a market capitalization of $171.94 million, a price-to-earnings ratio of -2.15 and a beta of 2.37. The firm has a 50 day moving average of $7.22 and a 200 day moving average of $7.47.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Friday, May 8th. The biotechnology company reported ($0.95) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.08. The business had revenue of $2.06 million during the quarter, compared to analyst estimates of $6.30 million. Arcturus Therapeutics had a negative net margin of 143.80% and a negative return on equity of 36.55%. On average, analysts predict that Arcturus Therapeutics will post -3.99 EPS for the current year.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ARCT. Osaic Holdings Inc. raised its position in shares of Arcturus Therapeutics by 51.8% during the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 738 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of Arcturus Therapeutics by 163.4% during the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 2,586 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new position in shares of Arcturus Therapeutics during the fourth quarter worth $64,000. Intech Investment Management LLC purchased a new position in Arcturus Therapeutics during the fourth quarter valued at $70,000. Finally, CANADA LIFE ASSURANCE Co grew its stake in Arcturus Therapeutics by 65.1% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 12,009 shares of the biotechnology company’s stock valued at $73,000 after acquiring an additional 4,737 shares in the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.